Table 1.
Characteristics of Included Patients in This Study
| Characteristics | Total (n = 119)a | Pentasa (n = 61) | Asacol (n = 64) | P-value |
|---|---|---|---|---|
| Sex | 0.210 | |||
| Male | 73 (61.3) | 32 (52.5) | 41 (64.1) | |
| Female | 46 (38.7) | 29 (47.5) | 23 (35.9) | |
| Age (yr) | 42.0 ± 14.4 | 44.8 ± 15.0 | 39.6 ± 13.4 | 0.051 |
| Duration of disease (yr) | 10.7 ± 8.0 | 13.9 ± 8.2 | 7.5 ± 6.3 | 0.001 |
| Disease location | 0.030 | |||
| Total | 61 (51.3) | 33 (54.1) | 31 (48.4) | |
| Left-sided | 38 (31.9) | 22 (36.1) | 17 (26.6) | |
| Proctitis | 11 (9.2) | 2 (3.3) | 11 (17.2) | |
| Dose (mg/day) | 2,885 ± 1,020 | 3,138 ± 675 | 0.010 | |
| Azathioprine | 28 (23.5) | 8 (13.1) | 22 (34.4) | 0.010 |
| PPIs | 32 (26.9) | 15 (24.6) | 19 (29.7) | 0.550 |
| Dosing period (mon) | 36.1 ± 30.0 | 26.7 ± 25.2 | ||
| H2RAs | 36 (30.3) | 25 (41.0) | 13 (20.3) | 0.020 |
| Dosing period (mon) | 76.8 ± 58.3 | 29.6 ± 20.3 | ||
| Biologics | 17 (14.3) | 9 (14.8) | 9 (14.1) | 1.000 |
1.000Values are presented as number (%) or mean±standard deviation.
a
Six patients who switched their 5-ASA type were included in both Pentasa and Asacol group.
PPIs, proton pump inhibitors; H2RAs, H2 receptor antagonists; 5-ASA, 5- aminosalicylic acid.